Angle Share Discussion Threads

[radderssandy] 11/3/2024 08:32

Hi Digger, I sent an email to IG (with help from another poster) towards the end of January. I also attended the Shares presentation in February and had a good chat with IG afterwards.

As a LTH, I know AGL’s timelines can slip and it is frustrating. But I respect IG. He sent me a thorough & considered reply to my email (and it covered a number of topics) and I liked his lack of BS responses to my questions when I spoke to him.

I asked him about the Solaris/prostate study.

To summarise (Feb 2024)
There is regular and ongoing dialogue between AGL & Solaris. Solaris understand the need for the work that is being undertaken and want the best results from the samples.

The first part of the patient enrolment is done, which is the 100 samples (as per the Interim results).

IG emphasised that these samples are “precious̶1;, AGL are currently optimising the molecular solution and how they are most effectively going to analyse these samples.

They think prostate will get better results with RNA than DNA.

IG said they anticipate the results coming out in H2.

I said to IG that timelines have slipped and pushed it as far as I could do. It would appear that the company have “re-calibrated” their timelines to the Interim results and have rather airbrushed out any previous guidance. The company line is, that in the Interims, they promised headline results by the year end, which they achieved with the BiDetect announcement. To help improve adoption by the industry of CTC’s they prioritised these BiDetect results.

I think there is some ambiguity in the Interim’s presentation, I definitely understood it as being prostate & ovarian. But reading back the results RNS it is unspecific “Headline results from the Company's major clinical studies expected by the year end demonstrating key clinical applications of the Parsortix system for patient care”. The wording had changed in the November business update to “the first of which we expect to publish before the year end.” Which was the BiDetect.

It will be interesting to see what the Prelim results say on the progress made. I don’t doubt that the results will be good, it’s just they prioritised BiDetect and most things with AGL, unfortunately, are slower than anticipated.

[fhmktg] 11/3/2024 07:24

Yes digger.
I have asked investor relations last week, but no response.
It's as if they have stopped looking at diagnostic tests and are relying on simply supplying consumable test kits for researchers.
NOT what I invested for, over five years ago

[sawney] 11/3/2024 07:22

AGL is the new definition of patience...

[digger18] 10/3/2024 21:30

Am I correct in saying that we have not had any update on the Prostate trial and also Ovarian update?

[htrocka2] 10/3/2024 14:41

bones699....Maybe the company have an agenda of their own?.

[bones699] 10/3/2024 13:10

...and yet no commercial deals signed!

And why is that?

[radderssandy] 10/3/2024 10:52

You will note on AGL’s website that there are two different links to Parsortix under the Product Solutions link:

Parsortix PC1 system – clinical
“The first FDA cleared medical device for the capture and harvest of intact CTCs from metastatic breast cancer patient blood for subsequent user-validated analysis”


Parsortix PR1 system – research
“The Parsortix®PR1 system gives translational researchers the power to capture and harvest circulating tumour and other cells of interest…..”
For Research Use Only. Not For Use in Diagnostic Procedures.

There is now a clear differentiation on their website.

[bones699] 10/3/2024 07:41

....and yet nobody is buying any Parsortix machines...why because they are for research use only....even states this on the packaging box.....FACT!

And here lies the dilemma Newland trying to market a machine for testing all cancers but knowing full well its not fully FDA approved to do so!

Hence no commercial deals!

[amt] 10/3/2024 06:39

Even if it only is approved for Breast cancer in USA that costs the US over 20billion dollars per annum so if they can help get earlier treatments etc that would save billions per annum. AGL if they took just 1% of those billions it's tens of millions in revenue.

[htrocka2] 09/3/2024 22:35

What is the FDA guidance on Research Use Only products?

Under the FDA’s guidance issued in 2013, a product labeled Research Use Only is an In Vitro Diagnostic (IVD) product “that is in the laboratory research phase..'

With the FDA approval, this has gone well passed that stage,

[tbow112] 09/3/2024 21:08

"Research use only. Not for use in diagnostic procedures."

It is a very peculiar disclaimer. Why not say "Research use only. Not yet approved for diagnostic procedures."
That way you do not discourage some of the people that might be interested.

[htrocka2] 09/3/2024 17:48

More misleading garbage from 699...This is the truth.

[5oletrader] 09/3/2024 17:37

A very bearish point you raise @bones699 - AGL achieving FDA approval in the most common cancer in the world.-'Maybe' highlight to @spa the following and ask the question - how common is BREAST cancer?-• BREAST cancer accounts for 12.5% of ALL NEW annual cancer cases worldwide, making it the MOST COMMON CANCER in the WORLD.• BREAST cancer is the MOST commonly diagnosed cancer among U.S. women. Each year, about 30% of ALL NEWLY diagnosed cancers in women are BREAST cancer.• Approximately 13% (about ONE in EIGHT) of U.S. women are going to develop invasive BREAST cancer in the course of their life.• In 2023, an estimated 297,790 NEW CASES of invasive BREAST cancer are expected to be diagnosed in U.S. women, along with 55,720 new cases of DCIS.• In 2023, an estimated 2,800 new cases of invasive breast cancer are expected to be diagnosed in men. A man's lifetime risk of breast cancer is about 1 in 833.• There are currently more than FOUR MILLION women with a history of BREAST cancer in the United States. This includes women currently being treated and women who have finished treatment.-Ponder some of those numbers.-Https://seer.cancer.gov/statfacts/html/common.html

[bones699] 09/3/2024 15:20

Spa..Parsortix only FDA approved for testing breast cancer..96% of all cancers Parsortix is not approved..hence why no commercial deals to date no one is buying a machine that can only be used to test 4% of cancers!

[toffeeman] 09/3/2024 07:08

It's a disclaimer as the tests are not approved

[tbow112] 08/3/2024 20:53

That is a rather odd caption to the photo -
"Research use only. Not for use in diagnostic procedures."

[cocorico2009] 08/3/2024 12:40

Gap at 14 still needs to be filled

[spa362] 08/3/2024 10:41

Huge bargain currently at 15.27 to buy

[spa362] 08/3/2024 10:39

I agree. In fact AGL is no different from any other company at this stage of its cycle. The point here is that AGL has the advantage of a unique patented technology and FDA approval. ON that basis I am very happy to be a long term holder and am confident that commercial gains will follow - and that AGL will either grow considerably or (more likely) be bought out by a bigger fish at some point in the cycle. On the basis, the current valuation is far too low. Significant gains to come here for those that are prepared to be patient - far more likely than not...inevitably, there will be a price-moving RNS at some point

[adw198] 08/3/2024 09:59

I wouldn’t - it would mean they weren’t in a closed period!
Personally I think we will need a raise. Plenty of companies do it’s not the deathnail. What we really need is some news of commercial deals to get us moving. If we do this will shoot right up and if we don’t it’ll stagnate and drop back. We place our bets - or sit on the sidelines shouting for attention when not even involved :)

[htrocka2] 08/3/2024 09:55

Adw198.....I shouldn't worry about...you never know, the company might be playing bones at his game...I'd laugh my socks off if the next rns is a 'director's buy'.

[zeus19] 08/3/2024 08:22

I only have one account you sad little child. Enjoy spending your entire weekend on the BBs again

[bones699] 08/3/2024 08:17

Stick to your parody accounts Zeus19!